-
Rosopatamab: Unveiling the Potential of Anti-CD47 Therapy in Cancer Research(Post)
Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By bloc
SIRPα Inhibition: Clearing Tumors by Promoting Phagocytosis(Post)Cancer cells are adept at avoiding destruction by the immune system, often exploiting specific pathways to escape detection and elimination. One of these key mechanisms involves the SIRPα
Understanding Platelet Activation: A Comprehensive Overview(Post)Haemostasis · Platelet BiologyUnderstanding Platelet Activation: A Comprehensive OverviewPlatelet activation is the rapid, tightly controlled response by which circulating platelets change shape, rele
IL-9 Signaling and Its Impact on Immune Cell Regulation(Post)Interleukin-9 (IL-9) plays a critical role in the immune system, influencing a variety of biological functions across different immune cell types. This article provides an in-depth look at the sig
Biosimilar: Expanding Access to Monoclonal Antibody-Based Therapies(Post)1. What is a Biosimilar? A biosimilar is a biologic medical product that is highly similar to an already-approved reference biologic. While minor differences in clinically inactive compon
What is RNAi? All You Need to Know(Post)Molecular Biology · Gene SilencingWhat is RNAi? A Complete Guide to RNA InterferenceRNA interference (RNAi) is a conserved biological process in which small double-stranded RNA molecules silence gene
PD-1 PD-L1 Pathway Diagram(Page) Coronavirus Assays(Page)Coronavirus Assays | SARS-CoV-2 ELISA, Multiplex, Rapid & PCR | Assay Genie
Targeting Immune Checkpoints as Cancer Therapy(Post)In recent years, the field of oncology has witnessed a paradigm shift with the advent of immunotherapy, a treatment modality that harnesses the body's immune system to combat cancer. Among the mos
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research(Post)Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
Innate Lymphoid Cells: ILC1, ILC2 & ILC3(Page) Deprotonation: Unveiling the Chemistry Behind It(Post)Chemistry · Acid-BaseDeprotonation: Mechanism, pKa and Choosing the Right BaseDeprotonation is the removal of a proton from a molecule to give its conjugate base. Whether it happens, and how completel
Tigatuzumab: Advancing Cancer Research with Targeted Therapies(Post)Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mech
IL-1 Family Signaling: Unraveling the Molecular Orchestra of Immune Regulation(Post)The Interleukin-1 (IL-1) family represents a crucial group of signaling molecules that play a pivotal role in regulating the immune system and inflammatory responses. Comprising 11 members, inc
cGAS-STING Signalling: Pathway, Regulation and Key Assays(Post)Double-stranded DNA in the cytosol is always a mistake. A virus has uncoated, a mitochondrion has ruptured, a micronucleus has burst, or a chromosome has been broken and left unrepaired. cGAS treats
Emapalumab: Unlocking the Potential of Targeting IFN-γ in HLH Treatment(Post)Quick Facts About EmapalumabWhat is Emapalumab?Emapalumab is a fully human monoclonal antibody that neutralizes interferon-gamma (IFN-γ). It is the first FDA-approved therapy for primary
Flow Cytometry Antibodies(Page)Flow Cytometry Antibodies | 16,900+ Conjugates & Panel Builder | Assay Genie
Complement: The Brake Matters More Than the Trigger(Post)Complement is firing on your own cells right now. Not in response to anything — C3 hydrolyses spontaneously in plasma at a low, constant rate, and every hydrolysed molecule is a potential convertase
Unlocking the Potential of Anti-CD47 in Cancer Immunotherapy(Post)Quick Facts About RagifilimabWhat is Ragifilimab?Ragifilimab is an investigational anti-CD47 monoclonal antibody developed to block the CD47-SIRPα interaction, thereby enhancing macropha
Monalizumab: A Breakthrough in Cancer Immunotherapy Targeting NKG2A(Post)Quick Facts About MonalizumabWhat is Monalizumab?Monalizumab is a first-in-class immune checkpoint inhibitor targeting NKG2A, developed to enhance anti-tumor immune response by blocking